The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling
pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T …

Background Immune checkpoint inhibitors (ICI) are clinically active across multiple tumor
types but the associated immune-related adverse events (irAEs) lead to treatment delays or …

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but are associated
with significant autoimmune endocrinopathies that pose both diagnostic and treatment …

Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for
numerous malignancies. However, due to their association with autoimmunity, ICIs have …

Abstract Hormone-receptor positive (HR+) breast cancer (BC)(including the luminal A and
the luminal B subtypes) is the most common type of tumor in women diagnosed with early …

Abstract Introduction Immune checkpoint inhibitors (ICIs) are widely used in the treatment of
many cancers as they improve clinical outcomes. However, ICIs have also been associated …

In recent years, a wide range of cancer immunotherapies have been developed and have
become increasingly important in cancer treatment across multiple oncologic diseases. In …

The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …

Objective To quantify the risk of immune-related adverse events (irAEs) in patients with pre-
existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage …